Mast Therapeutics
Mast, earlier called ADVENTRX, was a San Diego biotech whose fluorouracil modulator CoFactor reached phase 3 in colorectal cancer and failed; it later pursued sickle cell disease and merged into Savara in 2017.
Overview
Mast Therapeutics, formerly ADVENTRX Pharmaceuticals, developed ANX-510 (CoFactor), a folate analogue intended to enhance fluorouracil, through a phase 3 trial in metastatic colorectal cancer that did not show benefit, and later vepoloxamer for sickle cell crisis and heart failure, which also failed in phase 3. The company merged with Savara in 2017. Its trials remain on ClinicalTrials.gov under Mast and ADVENTRX as lead sponsor.
Scorecard
All companies- approved products +6
- modalities +2
- regions +6
- registry trials +30
Similar pages
not linked directly; found by shared links- CompanyAeterna Zentaris
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer and the tag ctgov-sponsor.
- CompanyCancer Prevention Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer and the tag ctgov-sponsor.
- CompanyNorgine
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer and the tag ctgov-sponsor.
- CompanyZeria Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Colorectal cancer and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.